Completed NA INTERVENTIONAL 1-arm NCT01969994

Absorption, Metabolism, and Excretion of (-)-[2-14C]Epicatechin in Humans

A Single-Center, Open-Label Study to Evaluate the Absorption, Metabolism, and Excretion of (-)-[2-14C]Epicatechin Following Oral Intake

Sponsor: Covance

Conditions ADME

Interventions (-)-[2-14C]epicatechin intake Controlled dietary background

Updated 5 times since 2017 Last updated: Oct 22, 2013 Started: Dec 31, 2009 Primary completion: Dec 31, 2009 Completion: Dec 31, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01969994, this NA trial focuses on ADME and remains completed. Sponsored by Covance, it has been updated 5 times since 2009, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Jan 2021 — Jul 2024 [monthly]

Completed NA
Sep 2020 — Jan 2021 [monthly]

Completed NA
Jan 2017 — Sep 2020 [monthly]

Completed NA

First recorded

Dec 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Covance
Mars, Inc.
The Institutes for Pharmaceutical Discovery, LLC

Data source: The Institutes for Pharmaceutical Discovery, LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Madison, United States